S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
NASDAQ:DRMA

Dermata Therapeutics Stock Forecast, Price & News

$3.13
+0.43 (+15.93%)
(As of 11/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.66
$3.16
50-Day Range
$2.33
$6.25
52-Week Range
$2.23
$6.95
Volume
212,468 shs
Average Volume
400,806 shs
Market Capitalization
$26.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive DRMA News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Dermata Therapeutics logo

About Dermata Therapeutics

Dermata Therapeutics Inc. is a privately held biotechnology company. It focused on treatment of medical and aesthetic skin diseases and conditions. The company's product pipeline consist DMT310 which is in clinical trial. Dermata Therapeutics Inc. is based in SAN DIEGO.

Headlines

Will Rally For Dermata Therapeutics Continue?
November 3, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRMA
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.50 per share

Profitability

Net Income
$-3.24 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$26.07 million
Optionable
Not Optionable

Company Calendar

Last Earnings
9/27/2021
Today
11/29/2021
Next Earnings (Estimated)
12/27/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

792nd out of 1,392 stocks

Pharmaceutical Preparations Industry

379th out of 670 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Dermata Therapeutics (NASDAQ:DRMA) Frequently Asked Questions

Is Dermata Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermata Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Dermata Therapeutics stock.
View analyst ratings for Dermata Therapeutics
or view top-rated stocks.

When is Dermata Therapeutics' next earnings date?

Dermata Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, December 27th 2021.
View our earnings forecast for Dermata Therapeutics
.

How were Dermata Therapeutics' earnings last quarter?

Dermata Therapeutics Inc (NASDAQ:DRMA) announced its earnings results on Monday, September, 27th. The company reported ($0.70) earnings per share for the quarter.
View Dermata Therapeutics' earnings history
.

What price target have analysts set for DRMA?

3 brokerages have issued 1-year target prices for Dermata Therapeutics' stock. Their forecasts range from $9.00 to $14.00. On average, they anticipate Dermata Therapeutics' stock price to reach $12.33 in the next year. This suggests a possible upside of 294.0% from the stock's current price.
View analysts' price targets for Dermata Therapeutics
or view top-rated stocks among Wall Street analysts.

When did Dermata Therapeutics IPO?

(DRMA) raised $18 million in an initial public offering on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00 per share.

What is Dermata Therapeutics' stock symbol?

Dermata Therapeutics trades on the NASDAQ under the ticker symbol "DRMA."

Who are Dermata Therapeutics' major shareholders?

Dermata Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.19%).

Which institutional investors are buying Dermata Therapeutics stock?

DRMA stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC.

How do I buy shares of Dermata Therapeutics?

Shares of DRMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dermata Therapeutics' stock price today?

One share of DRMA stock can currently be purchased for approximately $3.13.

How much money does Dermata Therapeutics make?

Dermata Therapeutics has a market capitalization of $26.07 million.

How many employees does Dermata Therapeutics have?

Dermata Therapeutics employs 2,021 workers across the globe.

What is Dermata Therapeutics' official website?

The official website for Dermata Therapeutics is www.dermatarx.com.

How can I contact Dermata Therapeutics?

The company can be reached via phone at 858-800-2543.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.